Home  |  Maps & directions  |  Find a doctor  |  Contact us  |  Classes & programs  |  Jobs  |  Baby gallery  |  Pay bill  |  Employees | Physicians

More about heart care

Other services

Heart care news

Show her you care about her heart

Patient shares his experience being saved by an AED

Automated External Defibrillators Donated to Community Organizations

More bullet

Judy      Novack

SCAD heart attack no match for Judy Novack.

Increase Text Size Reduce Text Size Reset Text Size to Default

St. Anthony's Cardiology Center

Cardiac clinical trials

St. Anthony’s physicians and staff regularly work with patients who opt to participate in clinical trials designed to test the effects of medications, medical devices and care protocols in the treatment of heart disorders and diseases. All clinical trials are overseen by a cardiologist or vascular surgeon, approved by St. Anthony’s Medical Center Institutional Review Board and coordinated by a Clinical Research Coordinator.

Ongoing clinical research trials:

Abbott BL01 Trial: A study with an Investigational Nutritional Supplement with AN777 versus Control Nutritional Supplement in patients with Myocardial Infarction, Congestive Heart Failure, Chronic Obstructive Pulmonary Disease and Pneumonia. The Investigational Nutritional Supplement with AN777 is formulated to increase lean muscle mass, improve overall health and decrease patient re-hospitalization rates. Patients ingest two packages of the nutritional supplement each day for 90 days and are followed with office visits to track any re-hospitalizations and events.

EUCLID Study: A study of Ticagrelor, which is already approved for use in cardiac patients, versus Clopidogrel in patients with peripheral vascular disease.   Patients will be followed every 4 months the first year and every 6 months after that for up to 36 months.  The study will determine if the use of either of these medications will decrease the occurrence of major cardiovascular events such as any cardiovascular occurrence, stroke, and myocardial infarction.

ODYSSEY Study: A study with an investigational injectable monoclonal antibody versus placebo in patients with acute coronary syndrome. Patients will be treated and followed for 64 months to cardiac events, stroke and heart related re-hospitalizations. The investigational injectable monoclonal antibody is intended to decrease LDL cholesterol and risks for cardiovascular events.

ABSORB Study:  A study randomizing patients to a new investigational bio-absorbable intracoronary device versus a regular intracoronary stent in patients having elective coronary revascularization for the first time in that coronary artery and meeting all the eligibility criteria. At a minimum, patients will be followed for 1 year with office visits and 4 more years with office or telephone visits.  Some patients may be asked to have an angiogram repeated at the 3 year time-point.  The study will determine safety and effectiveness of this brand new technology of absorbable coronary device.

IBE 12-04 Study: A study using a new investigational device to treat an aneurysm in the iliac artery alone or both the aorta and the iliac artery in patients meeting all the eligibility criteria.  Patients will be followed for 5 years, collecting information from visits and CT Scans that would normally be completed by the implanting surgeon.  This device allows the aneurysm to have a device while still preserving flow to the internal iliac artery, which is not able to be preserved with the current approved devices. 

GREAT Registry: A Registry which will collect data and information on patients who are treated with a currently approved and used device to treat aortic aneurysms.  Patients will be followed for 10 years, collecting information from visits and CT Scans that would normally be completed by the implanting surgeon. The Registry will collect information on safety and effectiveness of the current device. 

MISTIE II Study: A study randomizing patients to minimally invasive surgery plus clot dissolving medicine versus standard of care for patients with intra-cerebral hemorrhage meeting all of the eligibility criteria.  The study will determine if using clot dissolving medicine to reduce the size of the clot left in the brain after a hemorrhagic stroke will improve patient functional recovery after a stroke. 

For information about these and other clinical trials at St. Anthony’s, please contact our Clinical Research Coordinator at 314-525-1697

Back to top

St. Anthony's Medical Center logo

For information, please call our Health Access Line at 314-ANTHONY (268-4669) or 800-554-9550 or visit find a physician online.

Working as trusted partners, the physicians and employees of St. Anthony's Health System will deliver care distinguished by its demonstrated quality and personalized service. We will be visibly engaged in improving the health and well­ being of the communities we serve in South County and beyond. We will stand together, proud to set the standard for independent community health systems.